# Manual Claude Follow-up Applied

- Batch ID: `urology-aua-hourly-2026-05-20-06-redo1`
- Row range: `AI_Drafts!391:400`
- Claude flagged rows: `393`, `395`, `400`
- Rows replaced: `393`, `395`, `400`
- Replacement guard: passed against full AI_Drafts export with no findings
- Validator: passed
- Verifier lint: passed
- Final verifier counts: Pass 10, Needs Revision 0, Reject 0, Source Needed 0
- Refreshed prompt path: `/Users/abbasanwar/Desktop/Projects/MedSwipe/build/automation/claude_reviews/urology-aua-hourly-2026-05-20-06-redo1_prompt.txt`

## Replacement Concepts

- Row 393: Low-risk Ta NMIBC recurrence-free for five years -> shared decision-making about continuing surveillance.
- Row 395: Recurrent calcium oxalate stone former with persistent hypocitraturia and potassium citrate tablet intolerance -> tolerable citrate/alkali strategy with follow-up urine testing.
- Row 400: Culture-negative dysuria with antibiotic nonresponse -> evaluate alternative diagnoses rather than labeling recurrent UTI.

## Original Claude Flags

- Row 393: Duplicate/saturation risk: prior row 303 incomplete TURBT with visible residual papillary NMIBC tumor -> repeat resection/endoscopic treatment.
- Row 395: Duplicate/saturation risk: prior row 355 periodic imaging to assess stone activity in recurrent stone former on prevention therapy.
- Row 400: Duplicate/saturation risk: prior row 320 recurrent uncomplicated UTI avoiding daily antibiotics -> methenamine hippurate.
